Sepsis Therapeutics Market Projected to Reach Valuation of USD 6.2 Billion by 2028

Vantage Market Research

Jan 30, 2022

In terms of revenue, the Global Sepsis Therapeutics Market is expected to reach USD 6.2 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 7.3% from 2022 to 2028. The large number of therapeutic drugs which are under the different phases of clinical trials coupled with the innovation of novel options of treatment for septic shock is expected to fuel the market growth.

Key Findings:

  • Under the drug class segment, the Cephalosporin sub-segment is expected to grow at a significant rate driven by the wide use of drug class, individually or combined with the other drugs. The Cephalosporin is categorized into the first, second, third, and fourth generations. Cephalosporin has the broadest gram-negative bacterial coverage which is another factor that driving the market growth.
  • Asia Pacific is the fastest-growing region. The development in healthcare infrastructure by public and private hospitals coupled with demand for novel therapeutics among the patient population is driving regional growth.

Some of the key players in the Sepsis Therapeutics Market include - F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline Inc, Mylan N.V. , Allergan, Inc. are the major companies operating in Sepsis Therapeutics Market..

A large number of patients with sepsis and a high possibility of increasing the patient pool across the world is anticipated to drive the sepsis therapeutics market in the coming period of time. An increase in the epidemiological burden of sepsis enhances the demand for the development of drugs for the treatment of sepsis. The leading pharmaceutical companies are focusing on addressing these unmet medical needs by new product development. The growing base of the geriatric population and increasing incidence of sepsis in the elderly population has potential for market growth. The new approval and commercialization of novel therapeutic drugs are under the clinical trial study which is expected to drive the growth of the global sepsis therapeutics market. On the contrary, the lack of a quick diagnostic test for detecting the sepsis conditions and lack of awareness in the patients can possibly pose various challenges for growth in the sepsis therapeutics market.

Europe is expected to have a potential market for sepsis therapeutics market. The availability of a higher budget for the research & development in the field of sepsis treatment coupled with initiatives that are taken by private as well as government institutions for promoting awareness about sepsis is the factor driving the regional growth.